Reports Q4 revenue $84.71M, consensus $82.66M. Total orders received grew 24% to $88.2M. “Exiting fiscal 2024, we saw another quarter of record revenue and our seventh consecutive quarter of revenue growth. We continue to leverage our proprietary platform to add to our portfolio of solutions that deliver growth and margin expansion including our Express portfolio, NGS tools and recently, Twist-developed enzymes. We ended the quarter and the year exceeding our guidance across the board, closing out the fiscal year with $313.0 million in revenue, a gross margin of 45.1% in 4QFY24 and a strong cash position,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
- Absci, Twist Bioscience collaborate to design antibody using generative AI
- Xoma enters $15M royalty monetization arrangement with Twist Bioscience
- Twist Bioscience price target raised to $48 from $45 at Leerink
- Twist Bioscience appoints Mike Fero as chief information officer
Questions or Comments about the article? Write to editor@tipranks.com